BioCryst Pharmaceuticals, Inc. develops and commercializes medicines for hereditary angioedema and other rare diseases. Its commercial product ORLADEYO® (berotralstat) is an oral, once-daily plasma kallikrein inhibitor for HAE, and company updates commonly report ORLADEYO revenue, commercial execution, and financial results.
BioCryst news also covers pipeline and portfolio developments, including investigational plasma kallikrein inhibitor navenibart, rare-disease research programs, licensing arrangements, acquisitions, senior R&D leadership changes, investor conference activity, and Nasdaq inducement equity grants tied to new employee hiring.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BioCryst Pharmaceuticals (Nasdaq: BCRX) reported new findings from the APeX-S clinical trial on ORLADEYO (berotralstat), showcasing sustained attack-free days for patients over 96 weeks. Presented at the C1-inhibitor Deficiency & Angioedema Workshop in Budapest, the trial demonstrated a reduction in hereditary angioedema (HAE) attack rates across various demographics, including age and gender. This oral medication is designed for patients aged 12 and older, and the results affirm its safety and effectiveness, with mild adverse events reported. Patients aged 12-17 maintained an attack-free status 97% of the time, while older patients also showed significant improvements in attack reduction rates. The commitment to expand ORLADEYO's accessibility to HAE patients globally remains robust.
BioCryst Pharmaceuticals (BCRX) announced it will report its first quarter 2023 financial results on May 3, 2023. The management will host a conference call and webcast at 8:30 a.m. ET to discuss these results and provide a corporate update. Interested parties can access the live call by dialing the designated numbers or via the company's investor website. BioCryst focuses on developing novel oral medicines for rare diseases, with its product ORLADEYO (berotralstat) approved in the U.S. and several international markets. In addition, the company is advancing programs targeting the complement system, including the clinical development of BCX10013. More details are available on their website.